{"entity":{"id":"nct07567014","kind":"trial","name":"Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS","aka":[],"tldr":"A phase 2 trial of Emapalumab in Multiple myeloma, run by NYU Langone Health, not yet recruiting.","summary":"Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS is a phase 2 interventional study registered as NCT07567014 by NYU Langone Health, with 60 participants planned, started 2026-05-11 and due to reach its primary completion in 2028-05-31. Interventions recorded: Emapalumab. Conditions recorded: Multiple Myeloma, Large B-cell Lymphoma (LBCL).\n\nLinked to the drug Emapalumab because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.","status":"planned","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07567014","url":"https://clinicaltrials.gov/study/NCT07567014"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["emapalumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07567014","phase":"2","setting":"A Phase II Study of the Interferon Gamma Inhibitor Emapalumab for Prophylaxis of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Lymphoma and Multiple Myeloma Receiving Bispecific T-Cell Engagers","sponsor":"NYU Langone Health","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07567014/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"emapalumab","kind":"drug","name":"Emapalumab","route":"/drugs/emapalumab/"}]}}